Objectives: Determine the prevalence of suboptimal peak inspiratory flow rate (PIFR) and associated patient characteristics and compare PIFR measurements obtained with spirometry and In-Check DIAL® device in ambulatory patients with COPD. Methods: Patients underwent PIFR measurement with In-Check DIAL® device and pulmonary function testing with calibrated equipment. Group characteristics and lung function were compared for patients with suboptimal (≤ 60 L/min) and optimal (> 60 L/min) PIFR. Receiver operating curve analysis determined the best maximal forced inspiratory flow (FIF max) value in identifying optimal PIFR by gender and height. Results: From July 1, 2016 to January 31, 2018, a total of 303 patients with chronic obstructive pulmonary disease (COPD) had PIFR and pulmonary function measurements. Group mean age was 65.5 ± 11.3 years with equal gender distribution. Suboptimal PIFR was observed in 61 (20.1%) patients. A significant correlation was observed between PIFR and FIF max, inspiratory capacity and residual volume (RV) to total lung capacity (TLC) ratio.
Inhaled bronchodilators are frequently prescribed for symptomatic relief of dyspnea and to treat acute exacerbations in patients with chronic obstructive pulmonary disease (COPD). Over the past decade, advances in the treatment of COPD have resulted in a proliferation of inhaled bronchodilators and antiinflammatory agents and aerosol delivery devices, including metered dose inhalers, dry powder inhalers (DPI), soft mist inhalers and nebulizers. The expansion in the combinations of inhaled therapies and diversity of aerosol delivery devices presents a challenge to patients and providers. Patients must have the cognitive ability and manual dexterity to adequately perform specific inhalation maneuvers with a given aerosol delivery device according to the manufacturer's specifications in order to achieve adequate lower respiratory tract deposition.
1,2 Additionally, there is increasing awareness that aerosol delivery devices and patient factors can influence medication adherence and clinical outcomes.
3,4,5 Hence, current Global initiative for chronic Obstructive Lung Disease (GOLD) guidelines recommend that providers prescribe inhalation delivery devices based on an Introduction individual's ability and preference.
6
As a class of aerosol delivery devices, the DPI is effective and commonly used in the management of COPD. Its popularity is due to the compact size, convenience, ease of use and limited need for handbreath coordination, such that the DPI accounts for 60% of the international market of inhaled medications.
7
Currently, 10 commercial DPIs are available for delivery of long-acting bronchodilators and corticosteroids.
8
However, lower respiratory tract delivery from a DPI is dependent on a patient's inspiratory flow. The optimal peak inspiratory flow rate (PIFR) for adequate drug delivery from a Diskus DPI is reported to be greater than 60 L/min. 5, 7, 8 Furthermore, measurement of PIFR allows objective evaluation of a patient's ability to generate enough inspiratory force for effective drug delivery from a DPI and several commercially available devices are available to measure PIFR.
9
Another assessment of peak inspiratory flow is the maximal forced inspiratory flow (FIF max) that is measured with spirometry. However, there is limited data comparing the measurement of peak inspiratory flow using different devices in ambulatory patients with COPD. Thus, the aims of the study were to 1) determine the prevalence of a suboptimal PIFR and describe the associated patient characteristics and 2) compare PIFR measurements obtained with an InCheck DIAL® device and a calibrated spirometer in stable, ambulatory patients with COPD. 
Statistical Analysis
All values represent mean ± standard deviation. Patients were classified according to PIFR measurements classed as optimal (> 60 L/min) or suboptimal (PIFR < 60 L/min). A comparison of patient characteristics with optimal and suboptimal PIFR was performed using an unpaired t-test. Chi square analysis was performed to compare categorical variables between the PIFR groups. Pearson correlation was performed to assess the relationship of PIFR with FEV1, FVC, inspiratory capacity and residual volume (RV) to total lung capacity (TLC) ratio. In addition, a receiver operating curve (ROC) analysis was performed to determine the best FIF max value in identifying optimal PIFR for the entire cohort and for subgroups based on gender and height using Youden's Index. Logistic regression analysis was performed regarding the interaction of gender and height on PIFR. A p-value of ≤ 0.05 was considered statistically significant. The analysis was performed by using SAS version 12 (SAS Institute, Inc., Cary, North Carolina).
Cohort Characteristics
Over a 19-month period, 303 unique patients with COPD underwent spirometry and PIFR measurements with an In-Check DIAL®. The group mean age was 65.5 ± 11.3 years with an even gender distribution ( Table  1) . Spirometry measurements for the entire group showed the presence of moderate airflow obstruction as determined by 2007 GOLD guidelines.
12
Measurement of PIFR with In-Check DIAL® allowed separation of patients according to optimal (> 60 L/ min) and suboptimal PIFR (≤ 60 L/min) ( Table 1) . Sixty-one patients (20.1%) had a suboptimal PIFR value.
Relationship Between PIFR and Pulmonary Function Tests
In the suboptimal PIFR group, lung function measurements demonstrated a significantly lower FEV1, total lung capacity (TLC) and inspiratory capacity compared to the optimal PIFR group. In addition, the RV/TLC was significantly greater in the suboptimal PIFR group. A significant correlation was demonstrated between PIFR and inspiratory capacity as well as residual volume (RV)/TLC (Figures 1 and 2) . The correlation between PIFR and inspiratory capacity (r = 0.40, p< 0.0001) was stronger than the relationship between RV/TLC and PIFR (r = -0.19, p = 0.002).
Similarly, a strong correlation was observed between PIFR and FIF max (r = 0.65, p< 0.0001).
Receiver Operator Curve Analysis
In the suboptimal PIFR group, the mean FIF max value obtained by spirometry was 178.5 ± 56.9 L/ min, significantly lower than the FIF max value in the optimal PIFR group of 263.4 ± 89.9 L/min (p< 0.0001) ( (Figure 3) .
Influence of Gender and Height
A ROC analysis by gender found that, in males, a FIF max value of 244 L/min provided a positive predictive value of 94.7% (Sensitivity = 68.7%, Specificity = 77.3%, R-square = 0.1397) ( Table 2 ). In females, a FIF max value of 215 L/min yielded a positive predictive value of 87.4% (Sensitivity = 68.5%, Specificity = 71.8%, R-square = 0.1499) ( Table 2 ). Further analysis of the cohorts by gender and height according to PIFR performance revealed that in males shorter than 65 in., a suboptimal PIFR measurement was observed in 16.7% of males. In females shorter than 65 in., a suboptimal PIFR was observed in 27.4% of women (Table 3) . Both gender and height were independent predictors of suboptimal PIFR. However, when adding both to the same model, the effect was no longer significant suggesting the impact of gender was mediated through short stature. 20 Furthermore, these investigators also reported that short stature and gender were independent predictors of a suboptimal PIFR. Interestingly, several reports have found little to no relationship with FEV1 and PIFR. 5, 17, 18, 20, 21, 22 In the current report, we observed a suboptimal PIFR in 20% of patients with COPD and identified women, shorter stature and air trapping to be factors associated with a suboptimal use of a DPI. Mechanisms to explain these observations invoke weak respiratory muscles and/or the presence of intrinsic positive end expiratory pressure that do not allow patients to achieve an adequate inspiratory flow.
Current guidelines offer no recommendations regarding use of delivery devices in specific patient populations to improve patient outcomes. al examined the acute effects on lung function in a group of ambulatory patients with a mean PIFR of 53 ± 5 L/min that employed a randomized, open-label crossover design. 23 Compared to baseline, nebulizer administration of a long acting beta2-agonist resulted in greater improvements in FVC and inspiratory capacity than DPI drug delivery. Another group retrospectively identified a suboptimal PIFR, defined as ≤ 60 L/min against no resistance, in 52% of patients hospitalized with an acute exacerbation of COPD.
5 Patients with a suboptimal PIFR had a higher 30-day and 90-day readmission rate for COPD compared to the group with a PIFR > 60 L/min. Moreover, a multivariable analysis identified PIFR as the only significant variable associated with COPD readmissions. Furthermore, a cohort of 10 patients with a suboptimal PIFR prescribed nebulized bronchodilators upon discharge demonstrated reduced COPD-related 30-day and 90-day readmission rates compared with a similar group prescribed DPI delivered bronchodilators. However, to address the relationship between a suboptimal PIFR and clinical outcomes will require a prospective clinical trial comparing DPI and other drug delivery devices.
Investigators have attempted to correlate inspiratory flow measurements obtained with spirometry and other measuring devices. Earlier studies found positive correlations between PIFR assessments in smaller sample populations. 17, 18, 22, 24 In healthy individuals with asthma, COPD, neuromuscular disease, and non-respiratory disorders, Sehuelt et al reported that spirometry measurements of FIF max measured without resistance were moderately correlated with PIFR obtained with a device that simulated the internal resistance of the Diskus (R 2 = 0.58). 18 In patients with a PIFR > 60 L/min, 84% were correctly classified using spirometry measurement of FIF max with a cutoff value of 196 L/min.
18 Our study also 5, 7, 8, 15, 19, 20 In summary, 1 in 5 stable, ambulatory patients with COPD had suboptimal PIFR. Suboptimal PIFR measurements were identified more frequently in females, short stature individuals and those with air trapping. Spirometry determined values of FIF max corresponded with PIFR measurements according to gender and height. Spirometry allows identification of patients with a decreased FIF max based on gender and height that can be used as a physiologic threshold value for future interventional studies.
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